Clinical trials: Solid Tumor, completed
Solid Tumors
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors
In this study, the investigators examine using a combination of two types of HLA-A*2402 (or HLA-A*0201)-restricted epitope peptides, which were derived from VEGF-R1 and VEGF-R2 the safety, immunogenicity, and antitumor effect of…
- Trial name
- NCT01949688
- Testing
- HLA-A*2402 or A*0201 restricted peptides
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Shiga University
Relapsed Solid Tumors, Refractory Solid Tumors
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
This IND-exempt Phase I trial will establish the recommended Phase II (RP2D) dose of eribulin in combination with fixed doses of oral irinotecan in adolescents and young adults with relapsed or refractory solid tumors.
- Trial name
- NCT02596503
- Testing
- Eribulin, Irinotecan, Cefixime
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have…
- Trial name
- NCT00006456
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Leukemia, Lymphoma
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00019656
- Testing
- perifosine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Resistant or Refractory Solid Tumors
Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056 mesylate in cancer patients with resistant or…
- Trial name
- NCT04686383
- Testing
- CAL056 mesylate
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 17 people
- Sponsor
- Calgent Biotechnology Co., Ltd
Advanced Cancer, Solid Tumor
Randomized Controlled Trial of Integrated Early Palliative Care
This study verifies whether integrated Early Palliative Care for advanced cancer patients diagnosed due to a solid tumor improve quality of life and enhances the ability to overcome the current crisis.
- Trial name
- NCT03181854
- Testing
- Telephone coaching, Consultation with PCT doctor
- Where
- 10 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Seoul National University Hospital
Advanced Solid Tumor
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended…
- Trial name
- NCT04357756
- Testing
- YH001, Toripalimab
- Where
- 3 sites in Australia
- Volunteers
- 29 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel…
- Trial name
- NCT02051751
- Testing
- BYL719, Paclitaxel
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Advanced CEACAM6-expressing Solid Tumors
Study of BAY1834942 in Patients With Solid Tumors
This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the…
- Trial name
- NCT03596372
- Testing
- BAY1834942
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Bayer
Advanced Solid Tumors
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.
- Trial name
- NCT00827177
- Testing
- Treatment with ARQ 197 in combination with sorafenib
- Where
- 4 sites in United States, Italy
- Volunteers
- 87 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Unspecified Childhood Solid Tumor, Protocol Specific
Registration and Informed Consent Study for the Childhood Cancer Research Network
RATIONALE: Collecting informed consent from parents of children with cancer to register with the Childhood Cancer Research Network may help the study of cancer in the future.
- Trial name
- NCT00433394
- Testing
- cancer prevention intervention, educational intervention
- Where
- 21 sites in United States, Canada
- Volunteers
- 2,242 people
- Sponsor
- Children's Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
This phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04532372
- Testing
- Best Practice, Leflunomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Advanced Solid Tumors
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors.
- Trial name
- NCT03525795
- Testing
- CPI-1205, ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Constellation Pharmaceuticals
Anemia, Hodgkin Disease
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of once- weekly dosing of PROCRIT® (a glycoprotein that stimulates red blood cell production) versus placebo in the treatment of anemia in children with…
- Conditions
- Anemia, Hodgkin Disease, Leukemia, Lymphoma, Non-hodgkin
- Trial name
- NCT00261677
- Testing
- epoetin alfa
- Volunteers
- 224 people
- Sponsor
- Ortho Biotech Products, L.P.
Unspecified Childhood Solid Tumor, Protocol Specific
Gefitinib in Treating Children With Refractory Solid Tumors
Phase I trial to study the effectiveness of gefitinib in treating children who have refractory solid tumors. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth
- Trial name
- NCT00040781
- Testing
- gefitinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Mortality
90-Day Mortality After Emergency Department Discharge in Advanced Cancer
This retrospective observational study investigates factors associated with 90-day mortality among patients with advanced cancer who present to the emergency department (ED).
- Conditions
- Advanced Cancer, Mortality, Oncology, Emergency Department Admission
- Trial name
- CARE-90 (NCT07167095)
- Testing
- Retrospective Data Collection and Analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 1,250 people
- Sponsor
- Ankara Etlik City Hospital
Pancreatic Carcinoma, Pancreatic Neuroendocrine Tumor
Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy
Study objective: To describe the microflora characteristics of the pancreatic solid lesions via the tissue acquired via the endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B).
- Conditions
- Pancreatic Carcinoma, Pancreatic Neuroendocrine Tumor, Autoimmune Pancreatitis, Microflora
- Trial name
- NCT05171517
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Glioma, Other Solid Tumours
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
This is a phase 1/2A, open label, non-randomized study in patients with advanced solid tumours including malignant glioma
- Trial name
- NCT01792310
- Testing
- LAM561
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Laminar Pharmaceuticals
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT00348985
- Testing
- belinostat, bortezomib, pharmacological study
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.